Ligand Pharmaceuticals Incorporated Stock News

LGND vs. RGEN: Which Stock Is the Better Value Option?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

Ligand Pharmaceuticals, Inc. (NASDAQ:LGND ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO & Executive Director Matthew Kor

Ligand (LGND) delivered earnings and revenue surprises of -37.04% and 44.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on M

Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time hold the key to protecting your portfolio from big losses.

Detoxify your holdings by steering clear of these five stocks, Alarm.com (ALRM), Ligand (LGND), Radius Global (RADI), ADT Inc. (ADT) and Madison Square (MSGE).

Getting rid of fundamentally weak toxic stocks is important to shield your portfolio from losses. MSGE, MTLS, INNV and LGND are a few toxic stocks according to our model that you should dump now.

Ligand (LGND) reports encouraging first-quarter 2022 numbers by beating estimates on both counts. However, Captisol sales get hurt by lower demand for COVID-19 therapies.

Ligand (LGND) delivered earnings and revenue surprises of -4.92% and 33.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Simon Latimer - Head of Investor Relations John Higgins - CEO Matt Foehr

Ligand (LGND), Las Vegas Sands (LVS), CoStar (CSGP) and Blackbaud (BLKB) are a few toxic stocks that you should dump to avoid portfolio bleeding.

Ligand (LGND) is on track to spin-off its OmniAb business in the second half of 2022. It signs a merger agreement with a special purpose acquisition company (SPAC), Avista Public Acquisition Corp. for

Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 20

Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline.